Onco-nephrology: Kidney disease in the cancer patient: Introduction

Seminars in Nephrology

Volumn 30, Issue 6, 2010, Pages 531-533

  Humphreys, Benjamin D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; FEBUXOSTAT; RASBURICASE; VASCULOTROPIN INHIBITOR;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC KIDNEY DISEASE; COMORBIDITY; DISEASE ASSOCIATION; EDITORIAL; ELECTROLYTE DISTURBANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY FAILURE; KIDNEY INJURY; MALIGNANT NEOPLASTIC DISEASE; NEPHRECTOMY; NEPHROLOGY; NEPHROTOXICITY; ONCOLOGY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL RATE; SURVIVAL TIME; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUMOR LYSIS SYNDROME;

ANTINEOPLASTIC AGENTS; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; NEOPLASMS;

EID: 78649942783     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.09.001     Document Type: Editorial

References (13)

1. SEER cancer statistics review, 1975-2007. Bethesda, MD: National Cancer Institute Accessed on May 10, 2010. http://seer.cancer.gov/csr/1975_2007/.
2. Huang W.C., Levey A.S., Serio A.M., Snyder M., Vickers A.J., Raj G.V., et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006, 7:735-740.
3. Pasquini M, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: part I CIBMTR summary slides, 2009. CIBMTR Newsletter [serial online available at ] 2009. p. 7-11. Accessed on May 5, 2010. http://www.cibmtr.org.
4. Ando M., Ohashi K., Akiyama H., Sakamaki H., Morito T., Tsuchiya K., et al. Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors. Nephrol Dial Transplant 2010, 25:278-282.
5. Cohen E.P., Drobyski W.R., Moulder J.E. Significant increase in end-stage renal disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2007, 39:571-572.
6. Zhu X., Wu S., Dahut W.L., Parikh C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007, 49:186-193.
7. Eremina V., Jefferson J.A., Kowalewska J., Hochster H., Haas M., Weisstuch J., et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008, 358:1129-1136.
8. Wong G., Hayen A., Chapman J.R., Webster A.C., Wang J.J., Mitchell P., et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol 2009, 20:1341-1350.
9. Mau L.W., Liu J., Qiu Y., Guo H., Ishani A., Arneson T.J., et al. Trends in patient characteristics and first-year medical costs of older incident hemodialysis patients, 1995-2005. Am J Kidney Dis 2010, 55:549-557.
10. Jorgensen L., Heuch I., Jenssen T., Jacobsen B.K. Association of albuminuria and cancer incidence. J Am Soc Nephrol 2008, 19:992-998.
11. Maynard S., Epstein F.H., Karumanchi S.A. Preeclampsia and angiogenic imbalance. Annu Rev Med 2008, 59:61-78.
12. Patel T.V., Morgan J.A., Demetri G.D., George S., Maki R.G., Quigley M., et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008, 100:282-284.
13. Albini A., Pennesi G., Donatelli F., Cammarota R., De Flora S., Noonan D.M. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010, 102:14-25.